Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 180

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma

Open access
Jacquelot, Nicolas, Seillet, Cyril, Wang, Minyu, Pizzolla, Angela, Liao, Yang, Hediyeh-zadeh, Soroor, Grisaru-Tal, Sharon, Louis, Cynthia, Huang, Qiutong, Schreuder, Jaring, Souza-Fonseca-Guimaraes, Fernando, de Graaf, Carolyn A., Thia, Kevin, Macdonald, Sean, Camilleri, Mary, Luong, Kylie, Zhang, Shengbo, Chopin, Michael, Molden-Hauer, Tristan, Nutt, Stephen L., Umansky, Viktor, Ciric, Bogoljub, Groom, Joanna R., Foster, Paul S., Hansbro, Philip M., McKenzie, Andrew N. J., Gray, Daniel H. D., Behren, Andreas, Cebon, Jonathan, Vivier, Eric, Wicks, Ian P., Trapani, Joseph A., Munitz, Ariel, Davis, Melissa J., Shi, Wei, Neeson, Paul J., Belz, Gabrielle T. · 2021 · Nature Immunology

Abstract

Group 2 innate lymphoid cells (ILC2s) are essential to maintain tissue homeostasis. In cancer, ILC2s can harbor both pro-tumorigenic and anti-tumorigenic functions, but we know little about their underlying mechanisms or whether they could be clinically relevant or targeted to improve patient outcomes. Here, we found that high ILC2 infiltration in human melanoma was associated with a good clinical prognosis. ILC2s are critical producers of the cytokine granulocyte-macrophage colony-stimulating factor, which coordinates the recruitment and activation of eosinophils to enhance antitumor responses. Tumor-infiltrating ILC2s expressed programmed cell death protein-1, which limited their intratumoral accumulation, proliferation and antitumor effector functions. This inhibition could be overcome in vivo by combining interleukin-33-driven ILC2 activation with programmed cell death protein-1 blockade to significantly increase antitumor responses. Together, our results identified ILC2s as a critical immune cell type involved in melanoma immunity and revealed a potential synergistic approach to harness ILC2 function for antitumor immunotherapies. Group 2 innate lymphoid cells (ILC2s) are generally considered to have pro-tumor functions. However, Belz and colleagues demonstrate that ILC2s have anti-melanoma effects due to their high production of the inflammatory cytokine granulocyte-macrophage colony-stimulating factor in the tumor microenvironment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41590-021-00943-z

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 180

Metadata

Authors
Jacquelot, N., Seillet, C., Wang, M., Pizzolla, A., Liao, Y., Hediyeh-zadeh, S., Grisaru-Tal, S., Louis, C., Huang, Q., Schreuder, J., Souza-Fonseca-Guimaraes, F., de Graaf, C. A., Thia, K., Macdonald, S., Camilleri, M., Luong, K., Zhang, S., Chopin, M., Molden-Hauer, T., Nutt, S. L., Umansky, V., Ciric, B., Groom, J. R., Foster, P. S., Hansbro, P. M., McKenzie, A. N. J., Gray, D. H. D., Behren, A., Cebon, J., Vivier, E., Wicks, I. P., Trapani, J. A., Munitz, A., Davis, M. J., Shi, W., Neeson, P. J., & Belz, G. T.
Venue
Nature Immunology
Published
2021-06-07
Volume
22
Issue
7
Pages
851-864
ISSN
  • 1529-2908 (ISSN-L)
  • 1529-2916
OpenAlex
W3172691600
Cited by
180
References
14
FWCI
9.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. https://app.cochat.ai/papers/10.1038/s41590-021-00943-z
The paper
Jacquelot, N., Seillet, C., Wang, M., Pizzolla, A., Liao, Y., Hediyeh-zadeh, S., Grisaru-Tal, S., Louis, C., Huang, Q., Schreuder, J., Souza-Fonseca-Guimaraes, F., de Graaf, C. A., Thia, K., Macdonald, S., Camilleri, M., Luong, K., Zhang, S., Chopin, M., Molden-Hauer, T., . . . Belz, G. T. (2021). Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nature Immunology. https://doi.org/10.1038/s41590-021-00943-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.